5-years relapse-free survival and predictive factors identification in HR-positive HER2-negative breast cancer patients treated with anastrozole or fulvestrant neoadjuvant endocrine therapy: Pooled analysis of the CARMINA02 and HORGEN phase II trials

Authors :: Marina Pulido
Jérôme Lemonnier
N Quenel-Tueux
M.-A. Mouret-Reynier
B Sigal
Marc Debled
Thomas Bachelot
Simone Mathoulin-Pélissier
Hervé Bonnefoi
Lerebours
J-Y Pierga
Emmanuelle Fourme
C. Breton-Callu
L. Venat-Bouvet
Sofia Rivera
P. Kerbrat
Véronique Becette
C. Tunon de Lara
Florence Lerebours
Florence Dalenc
G. Mac Grogan
Source :: European Journal of Cancer. 92:S19
Publication Year :: 2018
Publisher :: Elsevier BV, 2018.

Subjects :: Oncology
Cancer Research
medicine.medical_specialty
Fulvestrant
business.industry
HER2 negative
Endocrine therapy
Anastrozole
medicine.disease
Relapse free survival
Breast cancer
Pooled analysis
Internal medicine
Medicine
business
medicine.drug

Full Text Access

Tools